The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

abstract：:KW-2149, a new mitomycin C (MMC) derivative, inhibited the growth of murine P388 leukemia in vitro at 20-fold lower concentrations than those of MMC. KW-2149 was also effective in inhibiting the growth of MMC-resistant P388 (P388/MMC) cells. To elucidate these characteristics of KW-2149, its uptake and efflux were com...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi E,Okabe M,Kono M,Arai H,Kasai M,Gomi K,Lee JH,Inaba M,Tsuruo T

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1-3, approved for second-line treatment of advanced renal cell carcinoma (RCC). Preclinical studies did not indicate potential for axitinib-induced delayed cardiac repolarization. METHODS:The effect of axitinib on corr...

journal_title：Cancer chemotherapy and pharmacology

authors： Ruiz-Garcia A,Houk BE,Pithavala YK,Toh M,Sarapa N,Tortorici MA

更新日期：2015-03-01 00:00:00

abstract：PURPOSE:Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Because HCC usually presents as an advanced disease and occurs in the background of liver cirrhosis, most patients are not suitable for treatment with curative intent, thus effective systemic chemotherapy is required. However, the ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kim SJ,Seo HY,Choi JG,Sul HR,Sung HJ,Park KH,Choi IK,Oh SC,Yoon SY,Seo JH,Choi CW,Kim BS,Shin SW,Kim YH,Kim JS

更新日期：2006-04-01 00:00:00

abstract：BACKGROUND:In a phase I clinical trial of oxaliplatin (OPT) in combination with paclitaxel (PXL), a pharmacokinetic interaction was observed when OPT was given as a 2-h i.v. infusion followed by a 1-h i.v. infusion of PXL. The purpose of this study was to use a rat model to evaluate whether the pharmacokinetic interact...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu J,Kraut EH,Balcerzak S,Grever M,D'Ambrosio S,Chan KK

更新日期：2002-12-01 00:00:00

abstract：:The novel anticancer compound GR63178A is being evaluated in the clinic, having demonstrated activity against a wide range of experimental tumour systems in animals without significant toxic side-effects being apparent. In this work, we have demonstrated significant antitumour action of this compound against one murin...

journal_title：Cancer chemotherapy and pharmacology

authors： French RC,Cummings J,MacLellan A,MacPherson JS,Ritchie AA,Smyth JF

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies. The purpose of this study was to assess the efficacy of a combination of docetaxel, capecitabine, and cisplatin (TXP) in patients diagnosed w...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu YS,Chen DR,Tseng LM,Yeh DC,Chen ST,Hsieh CM,Wang HC,Yeh HT,Kuo SH,Huang CS

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:We wished to define the maximum tolerated dose (MTD), toxicity, and pharmacokinetics of the novel isoflav-3-ene, NV06 (Phenoxodioltrade mark), a compound with a diphenolic structure related chemically and biologically to genistein and flavopiridol. PATIENTS AND METHODS:Twenty-one patients with advanced canc...

journal_title：Cancer chemotherapy and pharmacology

authors： de Souza PL,Liauw W,Links M,Pirabhahar S,Kelly G,Howes LG

更新日期：2006-10-01 00:00:00

abstract：PURPOSE:This study aimed to determine the correlation between DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) status and the response to streptozocin in advanced well-differentiated pancreatic neuroendocrine tumors (WD panNETs). METHODS:To test the hypothesis that MGMT deficiency was required for an al...

journal_title：Cancer chemotherapy and pharmacology

authors： Hijioka S,Sakuma K,Aoki M,Mizuno N,Kuwahara T,Okuno N,Hara K,Yatabe Y

更新日期：2019-01-01 00:00:00

abstract：PURPOSE:Tyrosine kinase inhibitors (TKI) that target MET signaling have shown promise in various types of cancer, including lung cancer. Combination strategies have been proposed and developed to increase their therapeutic index. Based on preclinical synergy between inhibition of MET and topoisomerase I, a phase I stud...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu SV,Groshen SG,Kelly K,Reckamp KL,Belani C,Synold TW,Goldkorn A,Gitlitz BJ,Cristea MC,Gong IY,Semrad TJ,Xu Y,Xu T,Koczywas M,Gandara DR,Newman EM

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-D-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. M...

journal_title：Cancer chemotherapy and pharmacology

authors： Philips KB,Kurtoglu M,Leung HJ,Liu H,Gao N,Lehrman MA,Murray TG,Lampidis TJ

更新日期：2014-02-01 00:00:00

abstract：:OSI-7836 (4'-thio-beta-D-arabinofuranosylcytosine) is a novel nucleoside analog in phase I clinical development for the treatment of cancer. As with other nucleoside analogs, the proposed mechanism of action involves phosphorylation to the triphosphate form followed by incorporation into cellular DNA, leading to cell ...

journal_title：Cancer chemotherapy and pharmacology

authors： Richardson F,Black C,Richardson K,Franks A,Wells E,Karimi S,Sennello G,Hart K,Meyer D,Emerson D,Brown E,LeRay J,Nilsson C,Tomkinson B,Bendele R

更新日期：2005-03-01 00:00:00

abstract：:Tumor-tissue and plasma concentrations of platinum were studied prospectively in two groups of eight patients who were suffering from advanced non-small-cell lung cancer. Treatments including two different schedules of cisplatin administration (25 vs 100 mg/m2 on day 1) were compared. At 30 min after the beginning of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Pujol JL,Cupissol D,Gestin-Boyer C,Bres J,Serrou B,Michel FB

更新日期：1990-01-01 00:00:00

abstract：:The effects of BCNU, CCNU, methyl-CCNU, streptozotocin, and chlorozotocin on calmodulin activity were studied in vitro and in vivo. Preincubation of BCNU, CCNU, and methyl-CCNU with calmodulin produced a concentration-dependent inhibition of in vitro calmodulin activity expressed as stimulation of cyclic nucleotide ph...

journal_title：Cancer chemotherapy and pharmacology

authors： Harrison SD Jr,Mann DM,Giles RC Jr

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:Neoadjuvant CT-P6, a trastuzumab biosimilar, demonstrated equivalent efficacy to reference trastuzumab in a phase 3 trial of HER2-positive early-stage breast cancer (EBC) (NCT02162667). We report post hoc analyses evaluating pathological complete response (pCR) and breast pCR alongside additional efficacy and s...

journal_title：Cancer chemotherapy and pharmacology

authors： Esteva FJ,Baranau YV,Baryash V,Manikhas A,Moiseyenko V,Dzagnidze G,Zhavrid E,Boliukh D,Stroyakovskiy D,Pikiel J,Eniu AE,Li RK,Rusyn AV,Tiangco B,Lee SJ,Lee SY,Yu SY,Stebbing J

更新日期：2019-10-01 00:00:00

abstract：PURPOSE:The dolastatins are a class of naturally occurring cytotoxic peptides which function by inhibiting microtubule assembly and tubulin polymerization. Cemadotin is a synthetic analogue of dolastatin 15 with potent antiproliferative and preclinical antitumor activity. This report describes a phase I study to evalua...

journal_title：Cancer chemotherapy and pharmacology

authors： Supko JG,Lynch TJ,Clark JW,Fram R,Allen LF,Velagapudi R,Kufe DW,Eder JP Jr

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:The purpose of this investigation was to synthesize a series of carbonate and carbamate derivatives of 4-demethylpenclomedine (DM-PEN), the major plasma non-toxic metabolite of penclomedine (PEN) seen in patients. DM-PEN has been observed to be an active antitumor agent in mouse human xenograft tumor models and...

journal_title：Cancer chemotherapy and pharmacology

authors： Morgan LR,Struck RF,Waud WR,LeBlanc B,Rodgers AH,Jursic BS

更新日期：2009-09-01 00:00:00

abstract：:Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC)...

journal_title：Cancer chemotherapy and pharmacology

authors： Chatelut E,Chevreau C,Brunner V,Martinez M,Houin G,Bugat R,Canal P

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:To evaluate the antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a vascular disrupting agent currently under phase II clinical trials in combination with cancer chemotherapy, in rats bearing chemically induced primary mammary tumours. METHODS:Tumours were induced in female Wistar rats by in...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu JJ,Ching LM,Goldthorpe M,Sutherland R,Baguley BC,Kirker JA,McKeage MJ

更新日期：2007-04-01 00:00:00

abstract：:The intra-cellular uptake of the weakly basic radiosensitiser pimonidazole (PIMO) was determined as a function of the pigmentation of Na11+ human melanotic melanoma cells in vitro. Two experimental conditions were considered: exponentially growing cells (Exp.) and plateau-phase cells (PI.). The melanin content of Na11...

journal_title：Cancer chemotherapy and pharmacology

authors： el Gamoussi R,Threadgill MD,Prade M,Stratford IJ,Guichard M

更新日期：1993-01-01 00:00:00

abstract：:We investigated the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to two alkylating and crosslinking agents: chlorambucil and N,N',N"-triethylenethiophosphoramide (thiotepa). The cell lines studied in...

journal_title：Cancer chemotherapy and pharmacology

authors： Seidenfeld J,Komar KA,Naujokas MF,Block AL

更新日期：1986-01-01 00:00:00

abstract：:Isothiocyanate sulforaphane (SFN) is a potent cancer chemopreventive agent. We investigated the mechanisms underlying the anti-proliferative effects of SFN in the human colon carcinoma cell line, HT-29. We demonstrate that SFN inhibits the growth of HT-29 cells in a dose- and time-dependent manner. Treatment of serum-...

journal_title：Cancer chemotherapy and pharmacology

authors： Shen G,Xu C,Chen C,Hebbar V,Kong AN

更新日期：2006-02-01 00:00:00

abstract：PURPOSE:Arsenic compounds have been found to be effective in the treatment of acute promyelocytic leukemia through the downregulation of bcl-2 expression. Resistant ovarian cancer cells often overexpress bcl-2 or p53 proteins or both. We hypothesized that arsenic compounds, such as As2O3 and As2S3, could also be active...

journal_title：Cancer chemotherapy and pharmacology

authors： Du YH,Ho PC

更新日期：2001-06-01 00:00:00

abstract：:The consequences at the cardiac level of adriamycin treatment alone or in association with the cardiac glycoside beta-methyldigoxin, were evaluated with reference to the PEP/LVET ratio, heart rate, and minimum blood pressure. The variation usually seen in the PEP/LVET ratio when adriamycin is administered alone was no...

journal_title：Cancer chemotherapy and pharmacology

authors： Di Fronzo G,Bertuzzi A,Ronchi E,Villani FP,Ronchetti L

更新日期：1979-01-01 00:00:00

abstract：:Pharmacokinetic studies in 11 patients with multiple myeloma were undertaken on the first and last days of one course of chemotherapy. The drug was administered PO in single doses of 6-14 mg daily. Melphalan concentrations were determined by high-performance liquid chromatography. The interpatient variability of pharm...

journal_title：Cancer chemotherapy and pharmacology

authors： Adair CG,Bridges JM,Desai ZR

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:There is considerable current interest in the use of thalidomide as a single agent or in combination with drugs such as cyclophosphamide in the treatment of multiple myeloma and other cancers. Our previous work has shown that thalidomide potentiates the antitumour activity of both cyclophosphamide and 5,6-dimet...

journal_title：Cancer chemotherapy and pharmacology

authors： Chung F,Wang LC,Kestell P,Baguley BC,Ching LM

更新日期：2004-05-01 00:00:00

abstract：BACKGROUND:Bevacizumab is approved for various cancers. This analysis aimed to comprehensively evaluate bevacizumab pharmacokinetics and the influence of patient variables on bevacizumab pharmacokinetics. METHODS:Rich and sparse bevacizumab serum concentrations were collected from Phase I through IV studies in early a...

journal_title：Cancer chemotherapy and pharmacology

authors： Han K,Peyret T,Marchand M,Quartino A,Gosselin NH,Girish S,Allison DE,Jin J

更新日期：2016-08-01 00:00:00

abstract：PURPOSE:The activity of 5-fluorouracil (5-FU) against colon cancer is enhanced by leucovorin and the combination of 5-FU and levamisole has activity in the adjuvant treatment of colonic malignancies. The combination of 5-FU with both leucovorin and levamisole may provide additional benefit in the treatment of colon can...

journal_title：Cancer chemotherapy and pharmacology

authors： Cleary JF,Arzoomanian R,Alberti D,Feierabend C,Storer B,Witt P,Carbone P,Wilding G

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:A recirculating isolated perfused rat liver model was used to investigate the hepatobiliary disposition of etoposide and the effects of cyclosporine A (CyA) on the pattern of drug disposition in the bile and uptake in the liver. METHODS:The portal vein, bile duct, and superior vena cava were cannulated in four...

journal_title：Cancer chemotherapy and pharmacology

authors： Khezrian M,Sheikholeslami B,Dadashzadeh S,Lavasani H,Rouini M

更新日期：2015-05-01 00:00:00

abstract：:Relationships between in vitro chemosensitivity and cell nuclear DNA content were investigated in malignant cells from 41 patients exhibiting advanced gastric carcinoma. The chemosensitivity was evaluated by measuring the succinate dehydrogenase (SD) activity in drug-exposed cancer cells and the DNA content was micros...

journal_title：Cancer chemotherapy and pharmacology

authors： Saito A,Korenaga D,Maehara Y,Baba H,Okamura T,Sugimachi K

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan Y,Huang Z,Fang L,Miao L,Gong L,Yu H,Yang H,Lei T,Mao W

更新日期：2015-09-01 00:00:00